Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was -$7.35K. Over 3 fiscal years it compounded at -3.1% a year.

Context

  • Accounts receivables amounted to 0.5% of revenue in FY2025.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$1.84K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
-$7.35K-96.9% YoY
LTMMar 2026
-$7.35K-91.1% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-96.9%——
3-year CAGR-3.1%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(7.35K) USD
Year-over-year change
+96.9%

Accounts Receivables vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 accounts receivables of $7.35K is the 5th largest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of -91.1% is the 2nd highest of 4, against a peer median of -100.0%.
  • Accounts receivables amounts to 0.5% of revenue for COEP, versus a peer median of 15.0%.
COEP Competitors Peer median
Accounts Receivables for COEP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$11.89M +385.7%—7.9%
CUECue Biopharma, Inc.LTM Mar 2026$7.25M -617.9%—22.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$968.41K ——290.7%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$12K ——0.5%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$7.35K -91.1%-3.1%0.5%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026$0 -100.0%——
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding COEP) $0-100.0%—15.0%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.45M)(37.57M)(21.27M)(10.88M)(11.92M)
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
Deferred Income Tax5.34M0000
Stock-Based Compensation1.9M0477.5K1.1M1.22M
Change in Working Capital(2.98M)(550.34K)1.73M(125.26K)(1.46M)
Accounts Receivables21.79K(8.08K)(30.9K)(234.74K)(7.35K)
Inventory(422.02K)0000
Accounts Payables(1.58M)(35.07K)1.32M(149.94K)(381.01K)
Other Working Capital(1M)(507.19K)437.31K259.42K(1.07M)
Other Non-Cash Items4.26M33.25M10.79M2.21M2.34M
Operating Cash Flow(4.49M)(3.88M)(7.24M)(6.65M)(8.6M)
Capital Expenditures(1.75M)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.75M)0000
Debt Repayment(1.62M)(2.42M)(575K)1.2M771.25K
Common Stock Issued10.14M3.27M5.29M100K12.97M
Common Stock Repurchased(247.17K)0000
Dividends Paid00000
Other Financing Activities(50.9K)4.63M200K500K0
Financing Cash Flow8.22M5.49M4.92M5.71M13.74M
Effect of Forex Changes00000
Net Change in Cash1.98M1.61M(2.32M)(936.25K)5.14M
Free Cash Flow(6.24M)(3.88M)(7.24M)(6.65M)(8.6M)

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.